- Hindi news
- Db original
- AstraZeneca Stopped Phase 3 Trials; 9 Pharmaceutical Companies Will Not Release Promising Premature Vaccines; And Kovaxin Will Be Available By Next Year
Due to the second powerful wave of Coronavirus, the economy of the country and the world is struggling with crisis. The number of new cases in unlock is increasing daily in India too. In such a situation, efforts to bring the Kovid-19 vaccine as soon as possible have received a major blow.
AstraZeneca has withheld trials of Kovyshield, a vaccine made at Oxford University in the United States, due to ill-treatment of a volunteer. At the same time, nine pharmaceutical companies in the US have promised that they will not launch the premature vaccine market.
Trials of the Oxford Vaccine Stopped
- The Phase-3 trials of Vaccine Coveshield of Oxford University and AstraZeneca, currently leading the vaccine race, have been temporarily halted. Actually, a Volunteer is taken ill. It is not understood whether this is a side effect of the vaccine shot or something. AstraZeneca has begun its investigation.
- The company issued a statement on Tuesday evening, saying that the standard review process has been stopped so that the safety data can be reviewed. AstraZeneca has not mentioned anything about the possible side effects. All that is said is that it is a “potent unexplained illness”.
- Health news site STAT was the first to report this news. A spokesperson for AstraZeneca has confirmed that it is in Volunteer UK. After this, AstraZeneca has stopped Phase-3 trials all over the world including America, India.
- In the past month itself, AstraZeneca has started tests on 30,000 people in the US. Apart from this, trials of this Oxford University vaccine have started in Britain, Brazil, South Africa as well as India. Serum Institute of India is conducting its trials in India.
Kovaxin will be available next year
- India's first indigenous Kovid-19 vaccine Kovaxin will be launched early next year. It has been developed by Bharat Biotech in association with ICMR. Kovaxin has started Phase-1 trials. The central government has approved Phase-2 trials from 7 September.
- Sanjay Rai, community medicine professor at AIIMS and principal investigator of the Kovid-19 vaccine, said the Phase-1 trials have been successfully completed. Phase-2 trials will be completed in October. Phase-3 trials will begin after this. This means that covaxin will become available by early 2021.
Efforts on phase-3 testing of Russian vaccine in India intensify
- Russia has approached India for phase-3 trials and production of its Kovid-19 vaccine Sputnik V. NITI Aayog member Dr. VK Paul said that the government understands the great importance of this offer of partnership with very special friends. There have been significant efforts on this.
- Dr. Paul, Member (Health), NITI Aayog, also said that Russia had approached several companies in the country to produce the vaccine. Four companies have also come forward for this. The government is trying to see how these companies can connect with Russian authorities.
9 pharmaceutical companies promised vaccine will be safe
- Nine pharmaceutical companies have issued a joint pledge, dismissing pressure to bring the Kovid-19 vaccine ahead of the US presidential elections. He has said in this that the safety of people who will be vaccinated will be at the top.
- The CEOs of AstraZeneca, BioNtech, GlaxoSmithline (GSK), Johnson & Johnson, Merck (MSD), Moderna, Novavax, Pfizer and Sanofi have signed on to the pledge. The initiative comes at a time when US President Donald Trump is trying to get treatment and vaccine approved as soon as possible to fight the epidemic.
- Trump also hinted on Monday that the United States may approve the Kovid-19 vaccine before the presidential elections on November 3, or in October. It is clear from the pledge of nine pharmaceutical companies that none of these companies will ask for premature approval before the trial ends.